$21.69
1.36% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US45781M1018
Symbol
INVA

Innoviva Stock price

$21.69
+3.43 18.78% 1M
+3.11 16.74% 6M
+4.34 25.01% YTD
+5.70 35.65% 1Y
+8.58 65.45% 5Y
+2.93 15.62% 10Y
+7.39 51.70% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.29 1.36%
ISIN
US45781M1018
Symbol
INVA
Sector
Industry

Key metrics

Market capitalization $1.36b
Enterprise Value $1.36b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 6.81
EV/Sales (TTM) EV/Sales 3.69
P/S ratio (TTM) P/S ratio 3.68
P/B ratio (TTM) P/B ratio 2.10
Revenue growth (TTM) Revenue growth 18.68%
Revenue (TTM) Revenue $369.84m
EBIT (operating result TTM) EBIT $182.49m
Free Cash Flow (TTM) Free Cash Flow $200.26m
Cash position $446.88m
EPS (TTM) EPS $-0.95
P/E forward 32.55
P/S forward 3.73
EV/Sales forward 3.74
Short interest 20.43%
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Innoviva:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Innoviva:

Buy
100%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
370 370
19% 19%
100%
- Direct Costs 34 34
20% 20%
9%
335 335
25% 25%
91%
- Selling and Administrative Expenses 113 113
4% 4%
30%
- Research and Development Expense 14 14
44% 44%
4%
208 208
55% 55%
56%
- Depreciation and Amortization 26 26
6% 6%
7%
EBIT (Operating Income) EBIT 182 182
66% 66%
49%
Net Profit -60 -60
133% 133%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
2 days ago
WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, ...
Neutral
Business Wire
4 days ago
WALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, singl...
Neutral
Business Wire
11 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following u...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Mr. Raifeld
Employees 127
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today